Houston、TXにおける脂肪肝の臨床試験
Houstonとその周辺地域（約30マイル以内）の拠点で、脂肪肝に関する13件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
被験者募集中第3相
- 89bio Clinical Study Site, Houston
- 89bio Clinical Study Site, Houston
- 89bio Clinical Study Site, Houston
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
被験者募集中第3相
- 89bio Clinical Study Site, Houston
- 89bio Clinical Study Site, Houston
- 89bio Clinical Study Site, Houston
- 他1件
A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
被験者募集中第3相
- GSK Investigational Site, Houston
- GSK Investigational Site, Bellaire · 7マイル先
- GSK Investigational Site, Humble · 17マイル先
A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
被験者募集中第3相
- GSK Investigational Site, Bellaire · 7マイル先
- GSK Investigational Site, Humble · 17マイル先
A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
被験者募集中第2相
- Pioneer Research Solutions, Inc., Houston
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
被験者募集中第3相
- HRI- Medical Center, Houston
- Care Access - Houston, Houston
- Houston Research Institute, Houston
- 他3件
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
被験者募集中第3相
- Akero Clinical Study Site, Houston
- Akero Clinical Study Site, Houston
- Akero Clinical Study Site, Houston
- 他3件
A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
被験者募集中第2相
- Houston Research Institute - Medical Center, Houston
- Houston Research Institute, Houston
- Bellaire Clinical Research, Bellaire · 7マイル先
A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
被験者募集中第3相
- GSK Investigational Site, Houston
- GSK Investigational Site, Bellaire · 7マイル先
A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
被験者募集中第2相
- GSK Investigational Site, Houston
- GSK Investigational Site, Houston
- GSK Investigational Site, Houston
A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
被験者募集中第1/2相健康なボランティア歓迎
- Pioneer Research Solutions, Houston
NAFLD Clinical Care Pathway
被験者募集中健康なボランティア歓迎
- Michael E. DeBakey VA Medical Center, Houston, TX, Houston
Evaluation of Non-Invasive Tests for Metabolic Liver Disease
被験者募集中観察研究
- First Surgical Hospital, Bellaire · 7マイル先
他の都市における脂肪肝の試験
- San Antonio, TX17件の研究
- New York City, NY16件の研究
- Miami, FL16件の研究
- San Diego, CA14件の研究
- Austin, TX13件の研究
- Richmond, VA12件の研究
- Tucson, AZ10件の研究
- Chandler, AZ10件の研究
- Hialeah, FL9件の研究
- Dallas, TX9件の研究
- Orlando, FL9件の研究
- St. Louis, MO9件の研究
Houstonにおける他の研究
- 非小細胞肺癌145件の研究
- 乳がん126件の研究
- がん（全種類）121件の研究
- 転移性癌104件の研究
- 大腸癌102件の研究
- 卵巣がん89件の研究
- 急性骨髄性白血病85件の研究
- 肺がん78件の研究
- 前立腺がん76件の研究
- 子宮内膜がん68件の研究
- 膵臓がん61件の研究
- 悪性黒色腫59件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。